AltMountain

Rock Springs Capital

Baltimore, MD · CRD 168648
Hedge fund manager

Rock Springs Capital is an SEC-registered investment adviser based in Baltimore, MD that reports managing 2 hedge funds on Form ADV. It reports $2.4 billion in regulatory assets under management. Its private funds, of all types, hold $2.4 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +15.4% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +54.6% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$2.4 billionForm ADV Item 5.F
Gross assets of private funds
$2.4 billionAll private fund types, Form ADV
Hedge funds managed
22 private funds in total
Employees
17Form ADV Item 5.A
Registration
SEC-registered adviserCRD 168648
Latest Form ADV
03/24/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+15.4%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+54.6%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$2.0 billion104 positions, 2026-06-30
$90$122$155Q3 2024Q1 2025Q3 2025Q1 202613F est. $155S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+20.2%+14.8%
Q1 2026-3.9%-4.6%
Q4 2025+17.5%+2.4%
Q3 2025+17.8%+7.8%
Q2 2025+7.2%+10.4%
Q1 2025-7.7%-4.5%
Q4 2024-6.3%+2.1%
Q3 2024+4.4%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 107 share positions ($1,859,870,981) reported by Rock Springs Capital Management LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Revolution Medicines Inc9.59%
  • Travere Therapeutics Inc6.98%
  • Eli Lilly & Co6.14%
  • Madrigal Pharmaceuticals Inc4.80%
  • Mirum Pharmaceuticals Inc3.58%
  • Rhythm Pharmaceuticals Inc3.55%
  • Kymera Therapeutics Inc2.46%
  • Insmed Inc2.24%
  • Unitedhealth Group Inc1.82%
  • Scholar Rock Hldg Corp1.77%
StockValue% of 13F portfolioSharesShares vs prior quarter
Revolution Medicines Inc$178,423,4879.59%869,256-21.35%
Travere Therapeutics Inc$129,776,5256.98%2,204,085+1.15%
Eli Lilly & Co$114,203,7966.14%98,700Unchanged
Madrigal Pharmaceuticals Inc$89,326,4064.80%177,249+1.29%
Mirum Pharmaceuticals Inc$66,656,4493.58%779,790-2.30%
Rhythm Pharmaceuticals Inc$65,945,7193.55%692,598Unchanged
Kymera Therapeutics Inc$45,792,6492.46%409,631-9.60%
Insmed Inc$41,689,6352.24%365,250+0.86%
Unitedhealth Group Inc$33,863,1301.82%92,250+44.71%
Scholar Rock Hldg Corp$32,985,8411.77%682,654-4.58%
Ascendis Pharma A/s$32,807,5201.76%144,000-14.67%
Tenet Healthcare Corp$31,945,0001.72%125,000Unchanged
Minimed Group Inc$31,249,3501.68%1,605,000+5.59%
Irhythm Holdings Inc$31,137,1571.67%273,950+1.59%
Intuitive Surgical Inc$29,379,0181.58%72,250-5.51%
Argenx SE$28,767,3001.55%30,000-43.13%
Heartflow Inc$28,606,2501.54%575,000+0.26%
Dexcom Inc$25,326,1151.36%293,500-14.43%
Boston Scientific Corp$23,352,7501.26%535,000+1.23%
Tarsus Pharmaceuticals Inc$22,413,4401.21%285,122+2.90%
Amylyx Pharmaceuticals Inc$22,022,1231.18%756,774+51.43%
Celldex Therapeutics Inc New$21,174,8791.14%653,344-6.55%
Agilon Health Inc$20,892,3751.12%262,500Unchanged
Zai Lab LTD$20,843,0261.12%791,307-2.87%
Erasca Inc$20,603,0611.11%1,405,393+0.23%
Pharvaris N V$20,565,1231.11%648,333Unchanged
Structure Therapeutics Inc$20,022,7131.08%640,317Unchanged
Aclaris Therapeutics Inc$19,941,2751.07%3,791,117-12.46%
Xenon Pharmaceuticals Inc$19,515,7501.05%524,758-23.27%
Penumbra Inc$19,100,4001.03%60,000-48.16%
Avalyn Pharmaceuticals Inc$18,886,5341.02%662,918Unchanged
Parabilis Medicines Inc$18,640,4031.00%577,281-0.13%
Neurocrine Biosciences Inc$18,510,1201.00%130,500-9.84%
Enliven Therapeutics Inc$18,045,3290.97%393,659-15.27%
Hemab Therapeutics Hldgs Inc$17,746,3230.95%575,432Unchanged
Inspire Med SYS Inc$16,923,8400.91%244,000Unchanged
Danaher Corp Del$16,904,2650.91%76,300Unchanged
MBX Biosciences Inc$16,140,8410.87%275,347-7.67%
Omeros Corp$16,130,8020.87%847,206+17.91%
Agios Pharmaceuticals Inc$15,705,1390.84%472,335-11.31%
Newamsterdam Pharma Company$14,931,0690.80%613,942+5.35%
Dyne Therapeutics Inc$14,368,0100.77%891,869-5.34%
Ultragenyx Pharmaceutical In$13,904,0880.75%925,089-4.42%
Zenas Biopharma Inc$13,541,0170.73%502,077Unchanged
Caris Life Sciences Inc$13,431,2550.72%438,500-10.05%
Cytokinetics Inc$13,303,2080.72%201,839+7.37%
Bridgebio Pharma Inc$12,650,0500.68%192,250+32.82%
Cogent Biosciences Inc$12,467,4030.67%389,363-24.53%
Mineralys Therapeutics Inc$12,186,8190.66%484,951Unchanged
Summit Therapeutics Inc$12,090,6500.65%715,000Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 12 new positions, 9 sold out, 32 increased, 30 reduced and 33 unchanged.

Number of positions (a count, not dollars)

  • New positions12
  • Increased32
  • Unchanged33
  • Reduced30
  • Sold out9

New positions

StockValueShares
Latigo Biotherapeutics Inc$10,930,100654,497
Freenome Inc$10,666,215677,220
Abcellera Biologics Inc$4,012,250275,000
Ionis Pharmaceuticals Inc$2,924,57565,500
Teva Pharmaceutical Inds LTD$2,445,30061,750
Immunovant Inc$2,368,07970,103
Atea Pharmaceuticals Inc$2,259,160433,620
Celcuity Inc$2,028,79425,513
Climb Bio Inc$1,335,808116,461
Humana Inc$1,278,2603,350
Braveheart Bio Inc$1,228,90760,837
Compass Pathways PLC$295,79823,778

Sold out

StockValue at Jun 30, 2026Shares held then
Medtronic PLC$2,417,30730,900
Teva Pharmaceutical Inds LTD$1,998,92059,000
Dianthus Therapeutics Inc$1,981,37820,326
Altimmune Inc$1,433,254471,465
Surgery Partners Inc$1,411,20084,000
Oruka Therapeutics Inc$1,146,89412,051
Viking Therapeutics Inc$994,75525,500
Glaukos Corp$663,8604,750
Moonlake Immunotherapeutics$208,25110,696

Largest increases

StockChange in sharesChangeValue nowShares now
Unitedhealth Group Inc+28,500+44.71%$33,863,13092,250
Amylyx Pharmaceuticals Inc+257,010+51.43%$22,022,123756,774
Bridgebio Pharma Inc+47,500+32.82%$12,650,050192,250
Omeros Corp+128,707+17.91%$16,130,802847,206
Novo-nordisk A S+47,300+74.49%$4,200,428110,800
Minimed Group Inc+85,000+5.59%$31,249,3501,605,000
Travere Therapeutics Inc+25,016+1.15%$129,776,5252,204,085
Spyre Therapeutics Inc+15,292+36.19%$5,123,32057,546
Neurogene Inc+47,651+44.64%$4,295,436154,401
Olema Pharmaceuticals Inc+148,400+63.10%$3,314,114383,578
Madrigal Pharmaceuticals Inc+2,250+1.29%$89,326,406177,249
Cytokinetics Inc+13,859+7.37%$13,303,208201,839
Stryker Corporation+3,300+11.38%$8,895,09732,300
Newamsterdam Pharma Company+31,198+5.35%$14,931,069613,942
Sagimet Biosciences Inc+65,458+26.18%$3,116,725315,458
Tarsus Pharmaceuticals Inc+8,035+2.90%$22,413,440285,122
Phreesia Inc+51,600+7.40%$7,732,005748,500
Irhythm Holdings Inc+4,300+1.59%$31,137,157273,950
Ardelyx Inc+128,100+5.71%$8,104,9522,369,869
Immunome Inc+19,688+5.66%$7,901,785367,354

Largest reductions

StockChange in sharesChangeValue nowShares now
Revolution Medicines Inc-235,954-21.35%$178,423,487869,256
Argenx SE-22,750-43.13%$28,767,30030,000
Penumbra Inc-55,750-48.16%$19,100,40060,000
Alnylam Pharmaceuticals Inc-28,750-43.07%$9,376,12038,000
Azenta Inc-200,250-49.69%$7,073,948202,750
Xenon Pharmaceuticals Inc-159,149-23.27%$19,515,750524,758
Ascendis Pharma A/s-24,750-14.67%$32,807,520144,000
Kymera Therapeutics Inc-43,525-9.60%$45,792,649409,631
Dexcom Inc-49,500-14.43%$25,326,115293,500
Cogent Biosciences Inc-126,554-24.53%$12,467,403389,363
Enliven Therapeutics Inc-70,966-15.27%$18,045,329393,659
Aclaris Therapeutics Inc-539,415-12.46%$19,941,2753,791,117
Omada Health Inc-112,750-30.23%$5,415,803260,250
Vera Therapeutics Inc-71,378-16.69%$11,501,892356,206
Neurocrine Biosciences Inc-14,250-9.84%$18,510,120130,500
Agios Pharmaceuticals Inc-60,228-11.31%$15,705,139472,335
Intuitive Surgical Inc-4,210-5.51%$29,379,01872,250
Arcus Biosciences Inc-65,346-36.30%$2,961,513114,654
Scholar Rock Hldg Corp-32,798-4.58%$32,985,841682,654
Mirum Pharmaceuticals Inc-18,355-2.30%$66,656,449779,790

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (3)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (2)

As reported in the adviser's Form ADV filed Mar 27, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌​⁠